Several companies have initiated recalls of extended release versions of the first-line type 2 diabetes treatment metformin due to unsafe levels of N-nitrosodimethylamine (NDMA), a probable human carcinogen.

On May 28, the Food and Drug Administration (FDA) informed the public that testing had revealed unacceptable levels of NDMA in some extended-release metformin products. The agency urged five companies to recall affected products. Recalls were initiated by the following manufacturers: Granules Pharmaceuticals, Lupin Pharmaceuticals, Avkare (repackager for Amneal), PD-Rx Pharmaceuticals (repackager for Amneal), PD-Rx Pharmaceuticals (repackager for Marksans), The Harvard Drug Group (repackager for Apotex), and Preferred Pharmaceuticals (repackager for Marksans).

The FDA has since created a searchable list of all recalled extended-release metformin products that includes manufacturer name, NDC numbers, lot numbers, and expiration dates for all affected products.

We're here to help!

At Clark & DiStefano we are attentive, always focusing on the needs of our clients. We develop strategies that are tailored to each individual case, and we treat our clients as strategic partners in achieving a common goal. We endeavor to think outside of the box and formulate cost-effective strategies. Lastly, we believe in prompt communications with clients so they have predictability for reserve setting and sufficient time for studied pre-trial evaluations and recommendations.